BioArctic's founders intend to divest minor part of their shareholding
BioArctic AB (Nasdaq Stockholm: BIOA-B) announced that its two founders and main shareholders, Lars Lannfelt and P盲r Gellerfors, plan to sell a minor portion of their shareholdings in the company. The company disclosed this information in compliance with EU Market Abuse Regulation requirements.
BioArctic AB (Nasdaq Stockholm: BIOA-B) ha annunciato che i suoi due fondatori e principali azionisti, Lars Lannfelt and P盲r Gellerfors, intendono cedere una piccola parte delle loro partecipazioni nella societ脿. La societ脿 ha reso nota questa informazione in conformit脿 al regolamento UE sugli abusi di mercato.
BioArctic AB (Nasdaq Stockholm: BIOA-B) anunci贸 que sus dos fundadores y accionistas principales, Lars Lannfelt and P盲r Gellerfors, planean vender una peque帽a porci贸n de sus participaciones en la compa帽铆a. La empresa comunic贸 esta informaci贸n en cumplimiento de los requisitos del Reglamento de la UE sobre abuso de mercado.
BioArctic AB (Nasdaq Stockholm: BIOA-B)電� 霊� 彀诫鞛愳澊鞛� 欤检殧 欤检＜鞚� Lars Lannfelt and P盲r Gellerfors臧� 氤挫湢 欤检嫕鞚� 鞚茧秬毳� 靻岇暋 毵り皝頃� 瓿勴殟鞚措澕瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 鞚� 靷嫟鞚� EU 鞁滌灔雮毄 攴滌爼 鞖旉惮靷暛鞐� 霐半澕 瓿店皽頄堨姷雼堧嫟.
BioArctic AB (Nasdaq Stockholm: BIOA-B) a annonc茅 que ses deux fondateurs et principaux actionnaires, Lars Lannfelt and P盲r Gellerfors, pr茅voient de c茅der une petite partie de leurs participations dans la soci茅t茅. La soci茅t茅 a divulgu茅 cette information pour se conformer aux exigences du r猫glement europ茅en relatif aux abus de march茅.
BioArctic AB (Nasdaq Stockholm: BIOA-B) gab bekannt, dass seine beiden Gr眉nder und Hauptaktion盲re, Lars Lannfelt and P盲r Gellerfors, beabsichtigen, einen kleinen Teil ihrer Unternehmensanteile zu ver盲u脽ern. Das Unternehmen ver枚ffentlichte diese Information zur Erf眉llung der Anforderungen der EU-Verordnung zum Marktmissbrauch.
- None.
- Potential reduction in founders' ownership stake could signal decreased insider confidence
This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation.听The information was released for public disclosure, through the agency of the contact person below, on September 3, 2025, at 5:35 p.m. CET.
For further information, please contact:听
Oskar Bosson, Vice President Communications and Investor Relations
E-mail:听[email protected]
Telephone: +46 70听410 71 80
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi庐 (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter鈩� technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap/articles/market-capitalization-explained" title="Read: What Is Market Capitalization and How It Is Calculated" class="article-link" rel="noopener">Large Cap. For further information, please visit .
This information was brought to you by Cision
The following files are available for download:
| BioArctic's founders intend to divest minor part of their shareholding |
View original content:
SOURCE BioArctic
FAQ
What did BioArctic founders announce about their shareholdings on September 3, 2025?
Who are the main shareholders planning to reduce their stake in BioArctic?
When was BioArctic's share sale announcement made?
How can investors contact BioArctic regarding the founders' share sale?
